Tocilizumab not associated with increased infection risk after CAR T-cell therapy: Implications for COVID-19? Research Letter
| Authors: | Frigault, M. J.; Nikiforow, S.; Mansour, M. K.; Hu, Z. H.; Horowitz, M. M.; Riches, M. L.; Hematti, P.; Turtle, C. J.; Zhang, M. J.; Perales, M. A.; Pasquini, M. C. |
| Title: | Tocilizumab not associated with increased infection risk after CAR T-cell therapy: Implications for COVID-19? |
| Keywords: | aged; aged, 80 and over; middle aged; risk factors; drug effect; risk factor; monoclonal antibody; hematologic neoplasms; adoptive immunotherapy; immunotherapy, adoptive; virus pneumonia; hematologic disease; adverse event; complication; pandemic; cytokine release syndrome; pneumonia, viral; tocilizumab; antibodies, monoclonal, humanized; very elderly; humans; human; male; female; coronavirus infections; betacoronavirus; coronavirus infection; pandemics |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | 1 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-07-02 |
| Start Page: | 137 |
| End Page: | 139 |
| Language: | English |
| DOI: | 10.1182/blood.2020006216 |
| PUBMED: | 32457999 |
| PROVIDER: | scopus |
| PMCID: | PMC7332891 |
| DOI/URL: | |
| Notes: | Letter -- Export Date: 3 August 2020 -- Source: Scopus |
